Pfizer COVID Vaccine 90 Percent Effective in Trials, Company May Request Approval by End of November
FEATURES
- Who Is a Mormon? by Christopher D. Cunningham
- Protecting the Symbols of Christ’s Church: How a Trademark Lawsuit Aligns with Prophetic Guidance by Steve Densley, Jr.
- 746 Times: What a Word Cloud Revealed About the April 2026 General Conference by Patrick D. Degn
- Broadway’s Last Acceptable Bigotry by Joel Campbell
- An Experiment in Prayer: Ocean to Ice by Mike Loveridge
- What Joseph Smith Saw in Exodus That We’ve Been Missing by Alvin H. Andrew
- (Re)Discovering Lorenzo Ghiberti’s “Gates of Paradise” at the BYU Museum of Art by John Dye
- “What Is Required to See the Face of God?”—Come Follow Me Podcast: Exodus 19-20, 24, 31-34 by Scot and Maurine Proctor
- Shamar: What It Means to “Keep” the Commandments in Hebrew by Steve Densley, Jr.
- When You Only Have Five Minutes to Get Out by Carolyn Nicolaysen
















Comments | Return to Story
Pauline HarryNovember 13, 2020
No long-term safety has been proven in this 2-month trial. The study reports only .02% of the study group from ALL OVER THE WORLD which doesn’t take into account how many cases are there are there, nutrition, weather, or lifestyle. And now they’re ready to start vaccinating millions! Throw tons of money at it and see if anyone sticks around?
Pauline HarryNovember 12, 2020
Pfizer's CEO cashed out 60% of his stock on the same day the company unveiled the results of its COVID-19 vaccine trial. Could end up helping to spread the virus.
ADD A COMMENT